Whitehawk Therapeutics (NASDAQ:WHWK) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Whitehawk Therapeutics (NASDAQ:WHWK) to a strong sell rating in a research report released on Saturday morning.

WHWK has been the topic of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Whitehawk Therapeutics in a research note on Wednesday, October 8th. Zacks Research raised Whitehawk Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 7th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce”.

Whitehawk Therapeutics Stock Down 7.5%

WHWK stock opened at $2.22 on Friday. Whitehawk Therapeutics has a 52-week low of $1.39 and a 52-week high of $3.81. The firm has a market capitalization of $104.63 million, a PE ratio of -37.00 and a beta of 0.58. The business’s fifty day simple moving average is $2.05.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its earnings results on Thursday, August 7th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($1.25). Whitehawk Therapeutics had a net margin of 99.42% and a negative return on equity of 75.99%.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.